89bio Publishes Positive Results from Phase 2 ENTRIGUE

– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety...

Related Keywords

United States ,San Francisco ,California ,Deepakl Bhatt ,Hank Mansbach ,Bryan Martins ,Sheryl Seapy ,Linkedin ,Icahn School Of Medicine At Mount Sinai ,Lifesci Advisors ,Nasdaq ,Mount Sinai ,Nature Medicine ,Chief Medical Officer ,New England Journal ,Quarterly Report ,Safe Harbor ,Private Securities Litigation Reform Act ,Sci Advisors ,Valentin Fuster Professor ,Cardiovascular Medicine ,Icahn School ,Nasdaq Etnb ,89bio ,Nc ,